Introduction
Inflammatory bowel disease (IBD) is a chronic, multisystem inflammatory disorder frequently associated with extraintestinal manifestations (EIMs), affecting up to 50% of patients over the disease course. Among these, ocular involvement represents the third most commonly affected organ system, occurring in approximately 4–12% of patients. Some manifestations are associated with intestinal disease activity, whereas others follow an independent course and may precede or coincide with the diagnosis of IBD, but whether timing of onset carries prognostic significance is unknown.
Aims & Methods
The present study aimed to assessed whether ocular EIMs arising around IBD diagnosis identify a distinct inflammatory phenotype.
We conducted a retrospective register-based study of patients with IBD and documented ocular EIMs identified from the Swedish IBD Registry (SWIBREG). Patients were classified according to the timing of ocular EIM onset relative to IBD diagnosis as early (before or within ±12 months) or late (>12 months after diagnosis). In patients with multiple ocular manifestations, the first recorded event was used to define timing. Clinical characteristics and outcomes were compared using chi-square tests, with Monte Carlo simulation applied where appropriate. Associations were expressed as odds ratios with 95% confidence intervals.
Results
Among 5,148 active patients registered in the SWIBREG for the Centre for Digestive Diseases, Karolinska University Hospital, patients with ocular EIMs were identified (uveitis, episcleritis, scleritis, keratitis) were identified. Patients with dry eye syndrome were excluded to restrict the cohort to inflammatory conditions. In total, 59 patients (1%) met the inclusion criteria, of whom 15 (25%) were classified as early-onset and 44 (75%) as late-onset. Uveitis was the manifestation in all patients in the early-onset group (100%) compared with 66% in late-onset (p = 0.0067), and were less likely in patients with prior systemic therapy exposure (OR 0.15, 95% CI 0.03–0.70; p = 0.028). Early presentation was associated with an increased likelihood of therapy escalation (OR 7.8, 95% CI 2.1–29.4; p = 0.003), attributed to various indications, including underlying IBD and/or other EIM activity. No patients in either group received treatment escalation solely due to ocular disease. Ocular EIMs recurrence was more frequent in the late-onset group compared with the early-onset (68% vs 46%, p > 0.05). In contrast, among patients with recurrent disease, a higher proportion of early-onset cases experienced multiple recurrences (>3 episodes) compared with late-onset cases (85% vs 46%, p > 0.05). IBD phenotype, smoking, and coexistence of other EIMs did not differ significantly between groups (all p > 0.05).
Conclusion
Early ocular EIMs may mark a distinct multisystem inflammatory phenotype in IBD, characterized by uveitis predominance, a higher likelihood of therapy escalation and a distinct recurrence pattern. Timing of ocular involvement may therefore add clinically useful prognostic information beyond conventional IBD phenotype.
Disclosure
C. R. H. Hedin served as a speaker and/or advisory board member for AstraZeneca, Abbvie, Celltrion, Dr Falk Pharma and the Falk Foundation, Galapagos, Janssen, Lilly, Pfizer, Pharmacosmos, Ferring, Takeda, Tillotts Pharma, and received grant support from Tillotts and Takeda, outside the submitted work. has acted as national and/or local principal investigator for clinical trials for Janssen, Ferring, and AbbVie; S.L. Haas has served as a speaker and/or advisory board member for Alfasigma, Celltrion, Ferring, Janssen, Lilly, Mediahuset, Pfizer, Santax Medico, Takeda, and Tillotts Pharma and reveived grant support from Tillotts Pharma.